Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Please consider supporting us by disabling or pausing your ad blocker.
Comments
ting pang eng commented on FPI.
7 hours
·
translate
英科医疗科技股份有限公司
INTCO Medical Technology Co., Ltd.
全球英科，健康全球 Global INTCO Global Health
英科医疗大中华区产品价格调整通知函
尊敬的合作伙伴：
您好！
衷心感谢您长期以来对英科医疗的信任与支持。
受全球原油及化工大宗商品价格大幅上涨影响，行业整体成本大幅提升，一次性丁腈手套核心原材料急剧上涨，且呈持续攀升趋势。我司生产成本显著上升，经营压力持续加大。面对上述情况，我司已全力通过内控管控消化成本压力。但面对核心原材料成本骤增，为保障产品品质、稳定供货能力，维护双方长期稳定合作，经公司审慎研究决定：
自2026年9月9日起，根据产品规格和克重差异，英科医疗一次性丁腈手套产品价格上涨15-40元/箱不等；具体事项请与我司业务团队沟通咨询，我们将第一时间为您解答。
再次感谢您的理解与鼎力支持！英科医疗将一如既往坚守品质与服务，与您携手共进，稳健同行，共创长远发展。
顺颂商祺！
英科医疗科技股份有限公司
2026年9月8日
（右下角为公司地址及联系方式）
---
底部社交媒体配文：
#英科丁腈手套涨价 #英科涨价通知 #英科丁腈手套备货 受原材料成本上涨影响，英科一次性手套产品价...
INTCO Medical Technology Co., Ltd.
全球英科，健康全球 Global INTCO Global Health
英科医疗大中华区产品价格调整通知函
尊敬的合作伙伴：
您好！
衷心感谢您长期以来对英科医疗的信任与支持。
受全球原油及化工大宗商品价格大幅上涨影响，行业整体成本大幅提升，一次性丁腈手套核心原材料急剧上涨，且呈持续攀升趋势。我司生产成本显著上升，经营压力持续加大。面对上述情况，我司已全力通过内控管控消化成本压力。但面对核心原材料成本骤增，为保障产品品质、稳定供货能力，维护双方长期稳定合作，经公司审慎研究决定：
自2026年9月9日起，根据产品规格和克重差异，英科医疗一次性丁腈手套产品价格上涨15-40元/箱不等；具体事项请与我司业务团队沟通咨询，我们将第一时间为您解答。
再次感谢您的理解与鼎力支持！英科医疗将一如既往坚守品质与服务，与您携手共进，稳健同行，共创长远发展。
顺颂商祺！
英科医疗科技股份有限公司
2026年9月8日
（右下角为公司地址及联系方式）
---
底部社交媒体配文：
#英科丁腈手套涨价 #英科涨价通知 #英科丁腈手套备货 受原材料成本上涨影响，英科一次性手套产品价...
INTCO Medical Technology Co., Ltd.
Global INTCO Global Health
Notice on Product Price Adjustment in INTCO Medical's Greater China Region
Dear Partners,
Greetings!
We sincerely thank you for your long-term trust in and support for INTCO Medical.
Affected by the sharp rise in global crude oil and bulk chemical prices, the overall cost of the industry has increased significantly. The core raw material for disposable nitrile gloves has soared and continues to show an upward trend. Our production costs have risen significantly, and the pressure on operating performance continues to increase. In the face of this situation, our company has made every effort to absorb cost pressures through internal controls. However, given the surge in core raw material costs, in order to ensure product quality, stabilize supply capacity, and maintain long-term stable cooperation, our company has decided after careful study:
Starting from September 9, 2026, based on differences in product specifications and gram weights, the prices of INTCO Medical's disposable nitrile gloves will increase by 15-40 RMB/carton. For specific matters, please consult with our business team, and we will answer your questions as soon as possible.
Once again, thank you for your understanding and strong support! INTCO Medical will, as always, adhere to quality and service, and work hand in hand with you to move forward steadily and develop together.
Wishing you prosperous business!
INTCO Medical Technology Co., Ltd.
September 8, 2026
Global INTCO Global Health
Notice on Product Price Adjustment in INTCO Medical's Greater China Region
Dear Partners,
Greetings!
We sincerely thank you for your long-term trust in and support for INTCO Medical.
Affected by the sharp rise in global crude oil and bulk chemical prices, the overall cost of the industry has increased significantly. The core raw material for disposable nitrile gloves has soared and continues to show an upward trend. Our production costs have risen significantly, and the pressure on operating performance continues to increase. In the face of this situation, our company has made every effort to absorb cost pressures through internal controls. However, given the surge in core raw material costs, in order to ensure product quality, stabilize supply capacity, and maintain long-term stable cooperation, our company has decided after careful study:
Starting from September 9, 2026, based on differences in product specifications and gram weights, the prices of INTCO Medical's disposable nitrile gloves will increase by 15-40 RMB/carton. For specific matters, please consult with our business team, and we will answer your questions as soon as possible.
Once again, thank you for your understanding and strong support! INTCO Medical will, as always, adhere to quality and service, and work hand in hand with you to move forward steadily and develop together.
Wishing you prosperous business!
INTCO Medical Technology Co., Ltd.
September 8, 2026
The capital reduction is officially 100% complete.
The "Effective Date" has passed
· Date of completion: 14 August 2026 (the date it was lodged with the Registrar of Companies).
· The proposed reduction is now legally finalized and cannot be reversed.
The New Share Capital Structure
As stated in the announcement, the company's issued share capital is now reduced to RM282,286,743.36.
· Total ordinary shares: 2,227,909,141 (unchanged from before—your share count is the same).
· Total RCPS: 14,191,007 (down slightly from Q1 2026 as more RCPS converted).
· Important note: Since the share count didn't change, the share capital reduction was purely a book-keeping entry.
What happens to the Retained Earnings now?
· Before reduction (Q1 2026): Accumulated Losses of -RM205.6 million.
· Capital Reduction amount: The company wiped out RM600 million from the Share Capital account.
· New Retained Earnings: RM600m (wiped) – RM205.6m (previous losses) = approx. +RM394.4 million.
Perdana's balance sheet now officially has positive retained earnings for the first time in years.
What this means for you?
· Your shares: Exactly the same number. No dilution.
· No cash for you today: This is purely a balance sheet clean-up.
· The real payoff: Future dividends are now legally possible. Because they wiped out the negative retained earnings, Perdana can now pay dividends from future profits.
· Caveat: They can pay dividends, but they are still losing money operationally (Q1 2026 net loss of RM12.1M). Dividends won't happen until they return to consistent profitability.
Bottom line: The "financial engineering" is now fully done. The ball is now entirely on management to turn their operational cash flow into actual net profits with their new vessels.
The "Effective Date" has passed
· Date of completion: 14 August 2026 (the date it was lodged with the Registrar of Companies).
· The proposed reduction is now legally finalized and cannot be reversed.
The New Share Capital Structure
As stated in the announcement, the company's issued share capital is now reduced to RM282,286,743.36.
· Total ordinary shares: 2,227,909,141 (unchanged from before—your share count is the same).
· Total RCPS: 14,191,007 (down slightly from Q1 2026 as more RCPS converted).
· Important note: Since the share count didn't change, the share capital reduction was purely a book-keeping entry.
What happens to the Retained Earnings now?
· Before reduction (Q1 2026): Accumulated Losses of -RM205.6 million.
· Capital Reduction amount: The company wiped out RM600 million from the Share Capital account.
· New Retained Earnings: RM600m (wiped) – RM205.6m (previous losses) = approx. +RM394.4 million.
Perdana's balance sheet now officially has positive retained earnings for the first time in years.
What this means for you?
· Your shares: Exactly the same number. No dilution.
· No cash for you today: This is purely a balance sheet clean-up.
· The real payoff: Future dividends are now legally possible. Because they wiped out the negative retained earnings, Perdana can now pay dividends from future profits.
· Caveat: They can pay dividends, but they are still losing money operationally (Q1 2026 net loss of RM12.1M). Dividends won't happen until they return to consistent profitability.
Bottom line: The "financial engineering" is now fully done. The ball is now entirely on management to turn their operational cash flow into actual net profits with their new vessels.
这篇来自银河国际证券（CGS International）的分析报告，是一个非常值得注意的“行业拐点信号”。
简单来说：看好一直在赌的“中国厂商撑不住”这件事，可能正在发生。
让我把这篇新闻核心信息拆解成三个点，并告诉这对Hartalega 持仓意味着什么：
1. 核心信号：中国厂商开始“踩刹车”和“退出”了
这篇报道给出了过去两年手套股最大的利空——“中国倾销”正在发生实质性的变化：
· 中国扩产踩刹车： 过去几年一直在疯狂扩建产能的中国手套厂，终于放慢了脚步。
· 旧产能退出市场： 那些成本高、效率低、在价格战中亏损的老旧工厂，开始关停或倒闭。
· 数据验证： 报告指出中国手套厂2025年的销售量仅增长1.8%，但EBIT（息税前盈利）却暴跌39%。这说明，中国企业是在“牺牲利润来保销量”，这种模式是不可持续的。
2. 对 Hartalega 的直接利好：市场份额正在回流
分析明确指出：“马来西亚手套业在全球销量的市场份额已有回升迹象。”
· 中国厂商为了保持销量不得不亏本卖货，但亏损无法永远持续。当他们被迫退出市场时，谁接住了订单？答案是拥有最低成本结构和最高质量认证的马来西亚厂商——Hartalega 正是其中最大的受益者。
3. 为什么这个消息对持仓者很重要？（与 RHB 报告的对比）
· 之前的担忧（RHB报告）： 认为中国厂商会继续价格战，压制 ASP，导致 Hartalega 的未来黯淡。
· 现在的转折（银河国际）： 证明中国厂商已经精疲力尽，难以再发动持久的价格战。
这正是我选择 Hartalega 作为长期投资的核心逻辑：这是“一场钱包比谁厚的战壕战”。Hartalega 有 RM 11 亿净现金，能扛住几年亏损；但许多中国竞争对手没有，他们正在流血出局。
结论
1. 持Hartalega 不仅仅是“赌战争红利”。 这篇文章证明，即使没有伊朗战争，由于中国产能的收缩，马来西亚手套行业的基本面也正在发生结构性的改善。
2. 短期 Q2 利润下滑是有预期的，不要被吓到。 7月到9月（Q2）ASP 的回落和成本的错配，确实会让下一份财报很难看。这已经被市场完全计入了股价。
3. 既然中国厂商在退场，那么明年起，一旦全球需求恢复，ASP 将不再受制于中国低价倾销，而是会稳定在一个更健康的水平（可能回到 US$20-22 甚至更高）。
总结： 这篇新闻是手套行业“供给侧改革”的一个重要信号。持Hartalega 不是持有在了一个即将被中国击败的行业，而是持有在一个即将完成“大清洗”的幸存者身上。耐心是你的盟友。
简单来说：看好一直在赌的“中国厂商撑不住”这件事，可能正在发生。
让我把这篇新闻核心信息拆解成三个点，并告诉这对Hartalega 持仓意味着什么：
1. 核心信号：中国厂商开始“踩刹车”和“退出”了
这篇报道给出了过去两年手套股最大的利空——“中国倾销”正在发生实质性的变化：
· 中国扩产踩刹车： 过去几年一直在疯狂扩建产能的中国手套厂，终于放慢了脚步。
· 旧产能退出市场： 那些成本高、效率低、在价格战中亏损的老旧工厂，开始关停或倒闭。
· 数据验证： 报告指出中国手套厂2025年的销售量仅增长1.8%，但EBIT（息税前盈利）却暴跌39%。这说明，中国企业是在“牺牲利润来保销量”，这种模式是不可持续的。
2. 对 Hartalega 的直接利好：市场份额正在回流
分析明确指出：“马来西亚手套业在全球销量的市场份额已有回升迹象。”
· 中国厂商为了保持销量不得不亏本卖货，但亏损无法永远持续。当他们被迫退出市场时，谁接住了订单？答案是拥有最低成本结构和最高质量认证的马来西亚厂商——Hartalega 正是其中最大的受益者。
3. 为什么这个消息对持仓者很重要？（与 RHB 报告的对比）
· 之前的担忧（RHB报告）： 认为中国厂商会继续价格战，压制 ASP，导致 Hartalega 的未来黯淡。
· 现在的转折（银河国际）： 证明中国厂商已经精疲力尽，难以再发动持久的价格战。
这正是我选择 Hartalega 作为长期投资的核心逻辑：这是“一场钱包比谁厚的战壕战”。Hartalega 有 RM 11 亿净现金，能扛住几年亏损；但许多中国竞争对手没有，他们正在流血出局。
结论
1. 持Hartalega 不仅仅是“赌战争红利”。 这篇文章证明，即使没有伊朗战争，由于中国产能的收缩，马来西亚手套行业的基本面也正在发生结构性的改善。
2. 短期 Q2 利润下滑是有预期的，不要被吓到。 7月到9月（Q2）ASP 的回落和成本的错配，确实会让下一份财报很难看。这已经被市场完全计入了股价。
3. 既然中国厂商在退场，那么明年起，一旦全球需求恢复，ASP 将不再受制于中国低价倾销，而是会稳定在一个更健康的水平（可能回到 US$20-22 甚至更高）。
总结： 这篇新闻是手套行业“供给侧改革”的一个重要信号。持Hartalega 不是持有在了一个即将被中国击败的行业，而是持有在一个即将完成“大清洗”的幸存者身上。耐心是你的盟友。
（吉隆坡11日讯）随着中国手套扩产踩刹车，加上部分旧产能退出市场，分析看好，全球手套市场有望比预期更快达到健康的供需平衡，加上我国手套业在全球销量的市场份额已有回升迹象，意味着手套业终于迎来久违的转折点。
由于市场氛围改善，在顶级手套（TOPGLOV，7113，主要板医疗保健）领涨下，手套古“四大天王”今日齐齐走高。
银河国际证券在分析报告中指出，中国手套厂商2025年销售量仅增长约1.8%，但息税前盈利（EBIT）赚幅却按年下跌39%，反映中国厂商在全球供过于求及竞争加剧下，盈利能力持续承压。
由于市场氛围改善，在顶级手套（TOPGLOV，7113，主要板医疗保健）领涨下，手套古“四大天王”今日齐齐走高。
银河国际证券在分析报告中指出，中国手套厂商2025年销售量仅增长约1.8%，但息税前盈利（EBIT）赚幅却按年下跌39%，反映中国厂商在全球供过于求及竞争加剧下，盈利能力持续承压。
The War of Attrition: Why Intco’s Price War Will Fail, and Why Hartalega Will Survive
In the current market, many investors are panicking over Hartalega's (HARTA) upcoming Q2 profit collapse. They see the ASP (Average Selling Price) dropping from US19, and they assume the glove recovery is dead.
But if you look beneath the surface—through the lens of forensic accounting and the Munger/Buffett mental model—a very different picture emerges.
This is not a story of industry failure. It is a story of a "War of Attrition" between two giants. And the math proves that Hartalega is the one that will walk away victorious.
The "Illogical" Strategy of Intco
The global glove industry is currently an Oligopoly trapped in a brutal price war. China’s Intco Medical is violating the fundamental Law of Supply. Even though ASPs have crashed to US$17–19 per 1,000 pieces—well below their manufacturing cost—they are cranking their factories to full capacity and flooding Europe and Asia with cheap gloves.
Why would they do this?
To bankrupt their competitors and seize market share.
But where is the money coming from?
Intco doesn't have the massive cash pile that Hartalega has. They are funding this suicidal price war through state-backed, ultra-low-interest loans from Chinese banks, and by burning through the capital they raised during the COVID boom. They are using borrowed money to sell gloves at a loss.
Why Intco Will Lose (The Munger Inversion)
If we invert the question, it becomes clear: How long can Intco bleed cash?
Intco is betting that Hartalega will blink first and cut production. They are wrong.
Hartalega’s Fortress:
· Cash Pile: RM 1.1 Billion (Zero net debt).
· Lowest Cost Structure: Plant 9’s automation has reduced headcount by 27.3% and slashed manufacturing costs to ~US$11.50 per 1,000 pieces.
· US Market Moat: With 100%+ US tariffs on Chinese gloves, Hartalega owns a protected market where they can still generate healthy margins.
In an Oligopoly price war, the winner is not the one who sells the cheapest—it is the one who can bleed the longest. Hartalega can bleed for 3–4 years. Intco cannot survive 2 years burning borrowed cash.
The Q2 "Crash": Why You Shouldn't Panic
Many investors are terrified of Hartalega's Q2 FY2027 results (due in November). The math shows profits will drop from RM70M back down to ~RM20M–RM25M.
This is not a sign of failure. This is a working capital cycle.
In Q1, Hartalega strategically hoarded RM465M worth of raw materials to secure supply before gas tariffs and NBR prices spiked further. In Q2, they will be forced to consume that expensive inventory while selling into a lower ASP environment. This creates a temporary "cost mismatch."
The silver lining: By Q3, the expensive inventory will be depleted, and Hartalega will return to buying cheaper raw materials. The margin recovery will be swift.
The Key Takeaway: Focus on Cash, Not Paper Profits
Over the last 4 quarters, Hartalega generated RM 792 Million in Operating Cash Flow against RM 160 Million in Net Profit.
An unethical CEO might massage depreciation numbers to inflate paper profits, but you cannot massage the Cash Flow Statement. The cash either went out the door to buy machines, or it stayed in the bank. Hartalega's RM 1.1 Billion cash pile is real, and it is growing.
My Strategy: Survive the Bleed, Ride the Consolidation
I am holding my shares. Not because I believe in a "glove boom," but because I believe in the math.
1. Break-Even Analysis: In the current market (ASP US$19–20), Hartalega is still operating 80% above its break-even point. They are not at risk of bankruptcy.
2. The Game of Chicken: The current price war cannot last forever. When Intco runs out of cash and is forced to raise prices, Hartalega will be the last man standing, with the lowest cost structure and the cleanest balance sheet.
3. The Exit: When that consolidation occurs, the market will re-rate Hartalega violently to the upside.
The market is pricing Hartalega as if Intco will win. But the math proves Intco will run out of money before Hartalega runs out of patience.
Disclaimer: This is a personal analysis based on publicly available financial data and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
In the current market, many investors are panicking over Hartalega's (HARTA) upcoming Q2 profit collapse. They see the ASP (Average Selling Price) dropping from US19, and they assume the glove recovery is dead.
But if you look beneath the surface—through the lens of forensic accounting and the Munger/Buffett mental model—a very different picture emerges.
This is not a story of industry failure. It is a story of a "War of Attrition" between two giants. And the math proves that Hartalega is the one that will walk away victorious.
The "Illogical" Strategy of Intco
The global glove industry is currently an Oligopoly trapped in a brutal price war. China’s Intco Medical is violating the fundamental Law of Supply. Even though ASPs have crashed to US$17–19 per 1,000 pieces—well below their manufacturing cost—they are cranking their factories to full capacity and flooding Europe and Asia with cheap gloves.
Why would they do this?
To bankrupt their competitors and seize market share.
But where is the money coming from?
Intco doesn't have the massive cash pile that Hartalega has. They are funding this suicidal price war through state-backed, ultra-low-interest loans from Chinese banks, and by burning through the capital they raised during the COVID boom. They are using borrowed money to sell gloves at a loss.
Why Intco Will Lose (The Munger Inversion)
If we invert the question, it becomes clear: How long can Intco bleed cash?
Intco is betting that Hartalega will blink first and cut production. They are wrong.
Hartalega’s Fortress:
· Cash Pile: RM 1.1 Billion (Zero net debt).
· Lowest Cost Structure: Plant 9’s automation has reduced headcount by 27.3% and slashed manufacturing costs to ~US$11.50 per 1,000 pieces.
· US Market Moat: With 100%+ US tariffs on Chinese gloves, Hartalega owns a protected market where they can still generate healthy margins.
In an Oligopoly price war, the winner is not the one who sells the cheapest—it is the one who can bleed the longest. Hartalega can bleed for 3–4 years. Intco cannot survive 2 years burning borrowed cash.
The Q2 "Crash": Why You Shouldn't Panic
Many investors are terrified of Hartalega's Q2 FY2027 results (due in November). The math shows profits will drop from RM70M back down to ~RM20M–RM25M.
This is not a sign of failure. This is a working capital cycle.
In Q1, Hartalega strategically hoarded RM465M worth of raw materials to secure supply before gas tariffs and NBR prices spiked further. In Q2, they will be forced to consume that expensive inventory while selling into a lower ASP environment. This creates a temporary "cost mismatch."
The silver lining: By Q3, the expensive inventory will be depleted, and Hartalega will return to buying cheaper raw materials. The margin recovery will be swift.
The Key Takeaway: Focus on Cash, Not Paper Profits
Over the last 4 quarters, Hartalega generated RM 792 Million in Operating Cash Flow against RM 160 Million in Net Profit.
An unethical CEO might massage depreciation numbers to inflate paper profits, but you cannot massage the Cash Flow Statement. The cash either went out the door to buy machines, or it stayed in the bank. Hartalega's RM 1.1 Billion cash pile is real, and it is growing.
My Strategy: Survive the Bleed, Ride the Consolidation
I am holding my shares. Not because I believe in a "glove boom," but because I believe in the math.
1. Break-Even Analysis: In the current market (ASP US$19–20), Hartalega is still operating 80% above its break-even point. They are not at risk of bankruptcy.
2. The Game of Chicken: The current price war cannot last forever. When Intco runs out of cash and is forced to raise prices, Hartalega will be the last man standing, with the lowest cost structure and the cleanest balance sheet.
3. The Exit: When that consolidation occurs, the market will re-rate Hartalega violently to the upside.
The market is pricing Hartalega as if Intco will win. But the math proves Intco will run out of money before Hartalega runs out of patience.
Disclaimer: This is a personal analysis based on publicly available financial data and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
Hartalega: The Quiet Survivor
With Hartalega (HARTA) hovering around RM1.00 after its stellar Q1 FY2027 results, many investors are focusing on the volatility of Average Selling Prices (ASP) and the threat of Chinese competition. However, I believe the market is missing the bigger picture.
My conviction in this company is not based on the "war-driven ASP spike." It is based on Management’s capital allocation discipline and their structural cost advantage. Here is why I believe Hartalega remains the only relevant Malaysian glove maker for the long haul:
1. The "Efficiency Gap" vs. Chinese Competitors
We often hear that Chinese players (like Intco) will "undercut everyone." However, look at the hard numbers: Hartalega’s Plant 9 (NGC 1.5) reduces manufacturing costs by 16% and lowers headcount by 8% using AI vision systems and automated stripping.
The Chinese business model of "薄利多销" (small margins, high volume) works in a bull market, but it is unsustainable when raw material (NBR) costs spike and ASPs drop. When you sell at US$18-20 per 1,000 pieces, who survives? The manufacturer with the lowest cost per unit. Hartalega is consistently pushing that cost floor lower, while their competitors are bleeding cash to keep their massive factories running.
2. Capital Allocation: The Top Glove Contrast
If you want to see the difference between a "survivor" and a "casualty," look at the history of capital allocation. During the pandemic boom, many competitors (specifically Top Glove) misallocated billions by aggressively buying back shares at the absolute peak of the stock price (draining cash) and over-expanding.
Hartalega’s management did the opposite. They hoarded RM1.14 Billion in cash, maintained practically zero net debt, and only initiated share buybacks when the stock was trading below RM0.90 (as seen in their recent buyback records). They did not chase the meme-stock hype. They protected their balance sheet. This is the hallmark of a rational, long-term management team.
3. The US and European "Certification" Moat
Price is only one factor in the US and European medical supply chains. Quality and regulatory compliance are the true barriers to entry. It takes years of stringent audits (FDA 510k, CE Marking, ISO 13485) and proven reliability to become a trusted supplier to major US hospital networks.
When Chinese manufacturers redirect excess capacity to non-US markets to survive, they are fighting a price war in regions that will trade quality for cost. However, the $60 billion+ US/EU medical market will still pay a premium for reliability. Hartalega’s automation ensures consistency, and their long-standing track record ensures they remain relevant in these high-value markets.
4. The "Oil Tanker" Risk (The Cash Cushion)
The biggest risk to Hartalega today is the gas tariff hike and the NBR cost mismatch in Q2. However, even with a projected 65% drop in next quarter’s profits, Hartalega is not at risk of bankruptcy. They have RM1.14 Billion in cash, no net debt, and a 60% dividend policy. They can weather a 2-3 year price war while the weaker players (both local and Chinese) burn through their cash.
Conclusion:
The market is treating Hartalega like a "trading play" based on the Iran war. I treat it as a "Cigar Butt" with a generational capital allocator at the helm. I do not expect the stock to return to RM4.00. However, I am confident that over the next 3-5 years, Plant 9’s cost efficiencies and management’s disciplined capital deployment will allow Hartalega to steadily grow its EPS back to pre-war normalized levels.
When everyone is fighting over a shrinking pie, I'm betting on the one with the sharpest knife and the deepest pockets.
That is Hartalega.
With Hartalega (HARTA) hovering around RM1.00 after its stellar Q1 FY2027 results, many investors are focusing on the volatility of Average Selling Prices (ASP) and the threat of Chinese competition. However, I believe the market is missing the bigger picture.
My conviction in this company is not based on the "war-driven ASP spike." It is based on Management’s capital allocation discipline and their structural cost advantage. Here is why I believe Hartalega remains the only relevant Malaysian glove maker for the long haul:
1. The "Efficiency Gap" vs. Chinese Competitors
We often hear that Chinese players (like Intco) will "undercut everyone." However, look at the hard numbers: Hartalega’s Plant 9 (NGC 1.5) reduces manufacturing costs by 16% and lowers headcount by 8% using AI vision systems and automated stripping.
The Chinese business model of "薄利多销" (small margins, high volume) works in a bull market, but it is unsustainable when raw material (NBR) costs spike and ASPs drop. When you sell at US$18-20 per 1,000 pieces, who survives? The manufacturer with the lowest cost per unit. Hartalega is consistently pushing that cost floor lower, while their competitors are bleeding cash to keep their massive factories running.
2. Capital Allocation: The Top Glove Contrast
If you want to see the difference between a "survivor" and a "casualty," look at the history of capital allocation. During the pandemic boom, many competitors (specifically Top Glove) misallocated billions by aggressively buying back shares at the absolute peak of the stock price (draining cash) and over-expanding.
Hartalega’s management did the opposite. They hoarded RM1.14 Billion in cash, maintained practically zero net debt, and only initiated share buybacks when the stock was trading below RM0.90 (as seen in their recent buyback records). They did not chase the meme-stock hype. They protected their balance sheet. This is the hallmark of a rational, long-term management team.
3. The US and European "Certification" Moat
Price is only one factor in the US and European medical supply chains. Quality and regulatory compliance are the true barriers to entry. It takes years of stringent audits (FDA 510k, CE Marking, ISO 13485) and proven reliability to become a trusted supplier to major US hospital networks.
When Chinese manufacturers redirect excess capacity to non-US markets to survive, they are fighting a price war in regions that will trade quality for cost. However, the $60 billion+ US/EU medical market will still pay a premium for reliability. Hartalega’s automation ensures consistency, and their long-standing track record ensures they remain relevant in these high-value markets.
4. The "Oil Tanker" Risk (The Cash Cushion)
The biggest risk to Hartalega today is the gas tariff hike and the NBR cost mismatch in Q2. However, even with a projected 65% drop in next quarter’s profits, Hartalega is not at risk of bankruptcy. They have RM1.14 Billion in cash, no net debt, and a 60% dividend policy. They can weather a 2-3 year price war while the weaker players (both local and Chinese) burn through their cash.
Conclusion:
The market is treating Hartalega like a "trading play" based on the Iran war. I treat it as a "Cigar Butt" with a generational capital allocator at the helm. I do not expect the stock to return to RM4.00. However, I am confident that over the next 3-5 years, Plant 9’s cost efficiencies and management’s disciplined capital deployment will allow Hartalega to steadily grow its EPS back to pre-war normalized levels.
When everyone is fighting over a shrinking pie, I'm betting on the one with the sharpest knife and the deepest pockets.
That is Hartalega.
1. The New Contract (Accommodation Work Barge)
This is a clear positive for shareholders(short-to-medium term).
· Why it’s good: It proves that PPB’s core business is actively winning new work. A 241-day contract (with a 30-day extension option) guarantees steady revenue and utilization for that vessel well into 2027.
· What’s missing: The contract value is not disclosed (due to confidentiality). You don’t know the exact profit margin. However, because they are providing "crew and equipment" for 24-hour service, this is typically a high-margin, recurring revenue stream.
· Key date: The contract starts 9 July 2026 (just days away), so the cash flow benefit will begin almost immediately.
2. The Share Capital Reduction (High Court Order Granted)
This is a neutral-to-positive accounting exercise (long-term impact).
· What happened: The High Court approved the reduction on 30 July 2026. The company now just needs to lodge the sealed order with SSM (Companies Commission) for it to take effect.
· Is it cash or a book adjustment? it is strictly a book adjustment. There is no mention of cash payout.
· Why the company does this: Perdana likely uses this to wipe out accumulated losses on their balance sheet. By clearing past losses, their retained earnings account becomes clean.
· Why it matters to shareholders :
· No immediate cash — your wallet is unaffected.
· Future dividends: With accumulated losses wiped out, PPB will be legally able to pay dividends from future profits. This paves the way for potential cash returns to shareholders in the years ahead.
· Clean balance sheet: It makes the company look healthier to investors and banks, which helps them secure future loans for things like those new AHTS vessels they are building.
This is a clear positive for shareholders(short-to-medium term).
· Why it’s good: It proves that PPB’s core business is actively winning new work. A 241-day contract (with a 30-day extension option) guarantees steady revenue and utilization for that vessel well into 2027.
· What’s missing: The contract value is not disclosed (due to confidentiality). You don’t know the exact profit margin. However, because they are providing "crew and equipment" for 24-hour service, this is typically a high-margin, recurring revenue stream.
· Key date: The contract starts 9 July 2026 (just days away), so the cash flow benefit will begin almost immediately.
2. The Share Capital Reduction (High Court Order Granted)
This is a neutral-to-positive accounting exercise (long-term impact).
· What happened: The High Court approved the reduction on 30 July 2026. The company now just needs to lodge the sealed order with SSM (Companies Commission) for it to take effect.
· Is it cash or a book adjustment? it is strictly a book adjustment. There is no mention of cash payout.
· Why the company does this: Perdana likely uses this to wipe out accumulated losses on their balance sheet. By clearing past losses, their retained earnings account becomes clean.
· Why it matters to shareholders :
· No immediate cash — your wallet is unaffected.
· Future dividends: With accumulated losses wiped out, PPB will be legally able to pay dividends from future profits. This paves the way for potential cash returns to shareholders in the years ahead.
· Clean balance sheet: It makes the company look healthier to investors and banks, which helps them secure future loans for things like those new AHTS vessels they are building.
Let’s use the Munger/Buffett "Invert" principle to dissect,
On Cost in China is way lower than Malaysia." (Reality: FALSE)
This is the biggest myth being spread right now.
· The Data: In the Kenanga report, it explicitly stated: "Through automation, Malaysian glove makers have reduced production costs by ~20%, significantly narrowing the cost gap with Chinese manufacturers."
· Why it matters: China's Intco does not have a massive cost advantage anymore. Hartalega's Plant 9 automation has brought their cost per 1,000 pieces down to ~RM16.80. Chinese factories have rising labor costs and environmental compliance costs. The cost difference today is razor-thin.
On Supply way more than demand." (Reality: TRUE for Medical Gloves)
· Global capacity is ~530B pieces; demand is ~373B pieces. There is massive oversupply.
· However, this is a problem for weak players. Hartalega is not a weak player. In a price war, the strongest survivor wins. Hartalega has zero net debt and RM1.14 billion in cash. When the oversupply forces small, debt-ridden factories to close, Hartalega will pick up their market share at pennies on the dollar.
On Wasting time on this industry... spend time on other MOATs.
This is where you are partially right.
You are right that medical gloves do not have a permanent, 30-year moat. The moat is only temporary (cost automation).
However, if you look at the UOB Riverstone report, that proves that Cleanroom / Semiconductor gloves DO have a permanent moat.
· Why? Because it takes 20+ years of trust and stringent quality certifications to supply an AI/Semiconductor chip factory. Chinese competitors cannot easily break into that market.
The market is always right about the supply-demand math in the short term. But the market is frequently wrong about the long-term survivability of the best-in-class operator.
On Cost in China is way lower than Malaysia." (Reality: FALSE)
This is the biggest myth being spread right now.
· The Data: In the Kenanga report, it explicitly stated: "Through automation, Malaysian glove makers have reduced production costs by ~20%, significantly narrowing the cost gap with Chinese manufacturers."
· Why it matters: China's Intco does not have a massive cost advantage anymore. Hartalega's Plant 9 automation has brought their cost per 1,000 pieces down to ~RM16.80. Chinese factories have rising labor costs and environmental compliance costs. The cost difference today is razor-thin.
On Supply way more than demand." (Reality: TRUE for Medical Gloves)
· Global capacity is ~530B pieces; demand is ~373B pieces. There is massive oversupply.
· However, this is a problem for weak players. Hartalega is not a weak player. In a price war, the strongest survivor wins. Hartalega has zero net debt and RM1.14 billion in cash. When the oversupply forces small, debt-ridden factories to close, Hartalega will pick up their market share at pennies on the dollar.
On Wasting time on this industry... spend time on other MOATs.
This is where you are partially right.
You are right that medical gloves do not have a permanent, 30-year moat. The moat is only temporary (cost automation).
However, if you look at the UOB Riverstone report, that proves that Cleanroom / Semiconductor gloves DO have a permanent moat.
· Why? Because it takes 20+ years of trust and stringent quality certifications to supply an AI/Semiconductor chip factory. Chinese competitors cannot easily break into that market.
The market is always right about the supply-demand math in the short term. But the market is frequently wrong about the long-term survivability of the best-in-class operator.
Load more